Videos

Dr. Pecora on the Breast Cancer Prevention Trial

Michael T. Lewis, PhD, runs a research lab at the Baylor College of Medicine focused on understanding the role of hedgehog signaling in mammary gland development and breast cancer

Plenty of children are afraid to go to the doctor. Dennis Slamon used to look forward to it.

Investigators have reported an increased risk of invasive breast cancer in postmenopausal women who are or were cigarette smokers

Should genomic profiles be used routinely to determine which breast cancer patients receive adjuvant chemotherapy?

Dr. David Pearlstone from John Theurer Cancer Center Discusses Mammogram Deterrents

Dr. Lisa Carey Discusses the Need for Targeted Therapy in Triple Negative Breast Cancer (TNBC)

Exposure to air pollution at certain times in a woman's life can leave her more susceptible to premenopausal breast cancer

Contrary to the traditionally slow pace of research adoption, the American College of Surgeons Oncology Group's Z0011 trial has seemingly changed practice overnight

A breast cancer diagnosis is a highly distressing, life-changing experience

Dr. Edith Perez from the Mayo Clinic in Florida on Adjuvant Treatments for Breast Cancer

I have just returned from the 21st Interdisciplinary Conference of the National Consortium of Breast Centers

A team of researchers explored the use of drugs in terms of breast cancer prevention strategies

Evidence that surveillance by mammogram in breast cancer survivors has been lacking until now

Iniparib remains an intriguing therapeutic possibility despite failing to meet its phase III primary endpoints

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

Tamoxifen, a common drug used to treat breast cancer, works by blocking the effect of estrogen on tumor cells.

New research suggested that concern about pain may deter obese women from undergoing mammography, while a busy schedule may dissuade women aged less than 60 years

Editors' picks for this month's best Websites, news, resources, and online information for oncologists.

About 40% of insured women in the United States are not undergoing screening mammography at least every 2 years in keeping with guidelines from the USPSTF.

As the Avastin (bevacizumab) drama continues at the FDA, the National Comprehensive Cancer Network (NCCN) has weighed in.

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on important research taking place in the field of breast oncology.

CYP2D6 phenotype status does not predict tamoxifen efficacy in patients with early-stage breast cancer, according to a retrospective analysis of data from the Breast International Group

Breast cancer researcher Edith A. Perez, MD, is aiming to present more detailed study findings at national conferences later this year that will help clinicians better identify patients who would benefit from HER2 targeted treatment.

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Two studies presented at SABCS refined knowledge about how to prevent lymphedema in patients with breast cancer.

Debu Tripathy, MD, Co-leader Women's Breast Cancer Program at USC/Norris Comprehensive Cancer Center, on bone health considerations for patients with breast cancer.